XM does not provide services to residents of the United States of America.
R
R

Roche

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial

BUZZ-Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial Updates ** U.S.-listed shares of Israel-based therapy developer Compugen CGEN.TA fall ~3% to $1.62 premarket ** Switzerland-based Roche's ROG.S drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday ** CGEN
A
R

Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial

BUZZ-Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial ** U.S.-listed shares of Israel-based therapy developer Compugen CGEN.TA fall ~3% to $1.62 premarket ** Switzerland-based Roche's ROG.S drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday ** CGEN has colo
A
R

European shares fall on French election uncertainty; log weekly gain

UPDATE 2-European shares fall on French election uncertainty; log weekly gain For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window STOXX 600 down 0.2%, eyes on French election UK midcaps close at one-month high Aixtron rallies on strong orders Updated at 1600 GMT By Shristi Achar A, Sruthi Shankar and Jesus Calero July 5 (Reuters) - European shares fell on Friday, weighed down by losses in banks and energy stocks as investors became more caut
A
R
A
E
F
U
G

Roche Says FDA Approves Genentech’S Vabysmo Prefilled Syringe (Pfs)

BRIEF-Roche Says FDA Approves Genentech’S Vabysmo Prefilled Syringe (Pfs) July 5 (Reuters) - ROCHE HOLDING AG ROG.S : FDA APPROVES GENENTECH’S VABYSMO PREFILLED SYRINGE (PFS) FOR THREE LEADING CAUSES OF VISION LOSS DESIGNED TO SIMPLIFY ADMINISTRATION, VABYSMO PFS PROVIDES RETINA SPECIALISTS A READY-TO-USE OPTIO VABYSMO PFS IS FIRST AND ONLY SYR
R

Roche Holding seen down on plan to halt lung cancer drug trial

BUZZ-Roche Holding seen down on plan to halt lung cancer drug trial ** Shares of Swiss drugmaker Roche Holding ROG.S seen down 2.3% in Julius Baer pre-market trade following its plans to halt trial for lung cancer treatment after 'disappointing' results ** The company said its antibody drug tiragolumab (anti-TIGIT) in combination with its Tecentriq
R
J

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.